COMP <GO>
ICCC vs IMDX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
ImmuCell Corporation (NASDAQ) VS. Insight Molecular Diagnostics Inc. (NASDAQ) • 15-METRIC TALLY: ICCC 5
— IMDX 4
■ METRIC PARITY
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
options-implied-move
—
LAST: $3.18 (0.00%) • MKT CAP: $104.1M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. IMDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | IMDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 56.70% | -15.30 | IMDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.20% | -35.00% | +39.20 | ICCC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | -24.38% | +25.69 | ICCC | /fcf-yield <GO> |
| Operating Margin | 6.00% | -60.00% | +66.00 | ICCC | /operating-margins <GO> |
| Net Profit Margin | -3.80% | -1.20% | -2.60 | IMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 115.60% | -111.30 | IMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 41.5 | +8.94 | ICCC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.7M | $104.1M | -$10.3M | IMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | IMDX REV | ICCC GROSS % | IMDX GROSS % | ICCC FCF | IMDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $4.1M | 41.4% | 56.7% | $1.2M | -$25.4M |
| FY 2024 | $26.5M | $1.9M | 30.0% | 39.3% | -$107.8K | -$21.2M |
| FY 2023 | $17.5M | $1.5M | — | — | -$4.7M | -$23.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
IMDX // BETA —